Objective. Supra-renal fixation in endovascular aneurysm repair (SR-EVR) is used to improve the proximal seal of aortic stent grafts and appears to have minimal effect on serum creatinine. Serum cystatin C (CC) is a more sensitive marker of renal injury and, unlike creatinine, is unaffected by non-renal influence. The aim of this study was to assess the true renal effect of SR-EVR using this superior renal index. Methods. Consecutive patients undergoing SR-EVR were prospectively recruited and compared to control groups undergoing open aneurysm repair (OR) and colorectal resection (CR). Serum CC and creatinine clearance (CrC) were determined pre-operatively and at 3, 6 and 12 months post-surgery. Renal function was compared using analyses of covariance (ANCOVA). Results. Sixty-five patients (M:F; 52:13, median age 74 years) were enrolled (24 SR-EVR, 28 OR, 13 CR). Pre-operative renal function and risk factors were comparable (CC 1.04 mg/l, SR-EVR; 0.96 mg/l, OR; 0.97 mg/l, CR). Adjusting for baseline renal function, there was no significant difference in CC or CrC between study and both control groups at 3, 6 or 12-months post-operatively. Conclusion. Using cystatin C as a more sensitive renal index, there was no detectable evidence of kidney dysfunction at up to one-year following EVR with uncovered bare-metal supra-renal fixation. Ó
Introduction
Contemporary opinion supports the use of uncovered bare metal supra-renal (SR) fixation in devices for endovascular repair (EVR) of abdominal aortic aneurysm (AAA) for improved longer-term stent-graft durability. 1, 2 Some authors have also suggested that this practice may also serve to increase anatomical eligibility for EVR due to a reduction in the prohibitive proximal neck morphology observed in many cases. 3 Several uncontrolled studies have now been published assessing the safety of bare metal supra-renal fixation following SR-EVR. Although there is no current evidence of any adverse renal effect, biochemical renal assessment has relied almost exclusively on blood urea nitrogen (BUN) and serum creatinine (sCr) methods. 2,4e9 More recently, the low molecular weight protein cystatin C (CC) has been validated as a superior endogenous renal marker to sCr that may enable the detection of sub-clinical renal injury. 10, 11 Using this more sensitive renal index (serum CC), the aim of this study was to prospectively compare renal function in SR-EVR patients with conventional open AAA repairs (OR) and others undergoing laparotomy for non-vascular pathology.
Patients and Methods
This was a prospective, controlled trial of patients undergoing elective AAA repair at a major tertiary referral centre over a twelve-month period commencing May 2002. Full ethical approval was obtained and all patients were issued relevant information sheets with appropriate consent documentation prior to inclusion.
During the study period, all AAA patients undergoing elective aortic repair were considered for study inclusion. Suitable patients with anatomically eligible pathology were randomized as per EVAR-1 trial protocol 12 to either EVR (study group) or OR (control group). Consecutive primary endovascular repairs and open AAA repairs performed outside EVAR-1 supplemented the EVR and OR limbs respectively. In addition, another sequential but limited control series of patients undergoing resection for colorectal malignancy (CR) was also recruited. Pre-operative renal failure with a requirement for renal replacement therapy (i.e. haemo-or peritoneal dialysis) precluded study inclusion.
At study enrollment, patient factors recorded included sex, age, weight, smoking habit, maximal antero-posterior AAA neck and sac sizes (calibrated on CT scan) and medical co-morbidity. The pre-operative differential renal function in all patients undergoing AAA repair (EVR & OR) was assessed by radiolabelled DTPA (Diethylene Thiamine Penta-acetic Acid) scanning. EVR-related procedural variables recorded included device type, deployment success and radiological contrast load.
All patients were reviewed at follow-up intervals of 3, 6 and 12 months. Biochemical markers of renal function were recorded pre-operatively and at these specific time points. Serum creatinine (sCr/mmoll À1 ) was analyzed on an Olympus 2700 multi-channel analyser (Jaffé reaction-based) using the manufacturers supplied reagents (Olympus Instruments, London), providing a between-batch imprecision of less than 2% for each analyte. Creatinine clearance (CrC/ mlmin À1 ) values were then derived using the validated Cockroft-Gault formula. 13 A separate clotted blood sample was also taken for serum CC measurement. After centrifugation for 10 minutes at 3000 rpm, serum was withdrawn and stored at À40 C for later analysis. Serum CC determination was by particle-enhanced turbidimetric immunoassay (PETIA) using the Cobas MIRA Plus automated analyser. The DAKO Cystatin C PET Kit contains polystyrene particles of uniform size, chemically coupled with rabbit antibody against human CC. A reaction between these immunoparticles and CC in a patient specimen results in the formation of agglutinates and a concomitant change in absorbance signal at 340 nm. Interpolation on a calibration curve determines the CC concentration of a specimen with a typical coefficient of variance of less than 8%.
Radiological analysis of renal anatomy in AAA patients was by contrast enhanced CT scan and intraoperative angiography (EVR). Whereas all patients underwent pre-operative CT scanning, only EVR patients and those OR subjects within the EVAR-1 trial had 12-month follow-up images available for comparison. Individual multi-slice (5 mm) analysis was performed to assess both for the presence of post-operative renal infarcts and evidence of overall renal preservation (bipolar size).
Data Analysis
All study information was anonymised and initially stored within a Microsoft Ò Excel (Microsoft Ltd., Reading, UK) spreadsheet. Relevant data was then exported to Minitab Ò Version-13 for Windows (Minitab Inc., PA, USA) software package for statistical and graphical analysis. 
Results
Sixty-five patients were recruited to the trial in the 12-month study period. Of these, 52 participants required elective AAA repair (24 EVR and 28 OR) whereas the remaining 13 underwent planned laparotomy for major colorectal resection (CR).
Twenty-two of the 52 AAA patients were randomized as part of the EVAR-1 trial (12 EVR & 10 OR). The remaining 30 cases were therefore primary aortic repairs (12 EVR and 18 OR) . Primary EVR stents were preferred for AAA repair in the setting of a hostile abdomen. Regarding the 18 primary OR patients outside the EVAR-1 trial, 4 eligible patients refused EVAR-randomization, 2 patients were <60-years old and 12 cases were morphologically unsuitable (short neck (n ¼ 7); mural thrombus (n ¼ 3) and excessive angulation (n ¼ 2)).
Pre-Operative Status
Group-specific patient and aneurysm-related factors are illustrated in Table 1 . There was no significant difference between the age range and sex distribution between groups. Similarly, all study limbs were analogous with respect to existing medical co-morbidity, smoking habit and renal function. Although no patient who required renal replacement therapy pre-operatively was enrolled for the study, those with renal impairment (defined as a 'screening' sCr value beyond the limits of the normal reference range 14 ) were not excluded.
For those patients presenting for AAA repair (EVR and OR), maximal antero-posterior sac and neck sizes were comparable (as per calibration for EVAR-1 trial 12 ). There were three cases of inflammatory AAA: one patient underwent 'primary' EVR following failed OR and the other two were randomized to the OR limb as part of EVAR-1. One aortic repair was performed for a symptomatic (non-ruptured) 44 mm AAA in a 52-year old patient with a strong family history of aneurysm rupture.
Peri-Operative Factors & Early Outcome
Two different types of supra-renally fixed endovascular stent were used in the study group. Thirteen patients received the Zenith device (Cook Inc., Bloomington, Ind.) with the other 11 cases undergoing EVR using the Cordis system (Johnson & Johnson, Miami, Florida). Median radiological contrast load (300 mg Iodine/ml) during endovascular repair was 163 ml (range 110e350 ml).
Stent-graft implantation was technically successful with satisfactory completion imaging in all but one case ('Patient 11'). Despite correct positioning prior to deployment, the Zenith device encroached on the left renal artery ostia with the covered segment of stent after release. The right renal artery appeared unaffected. Oliguria was noted as early as the theatre recovery room and this was unresponsive to aggressive guided (CVP) fluid resuscitation, frusemide and mannitol. Poor renal function was confirmed on an early post-operative DTPA scan, as the patient gradually became anuric, fluid overloaded and acidotic. This resulted in permanent haemo-dialysis dependence by the third post-operative day.
No early renal complications were observed in either of the control groups. Temporary supra-renal aortic cross clamping was required in 2 open AAA repairs in order to gain proximal control. In both of these cases there were no associated adverse renal sequelae.
The one early death of the entire series followed the primary EVR of a 76 mm AAA in a patient with known myelo-proliferative disorder and massive splenomegaly. Initially, his post-operative progress appeared satisfactory and he was actually discharged for further convalescence at day 6. Re-admitted two days later with sudden back pain, an urgent CT scan demonstrated no stentrelated problem. Within a week though, he had developed severe chest sepsis and a consumptive coagulopathy (DIC) that was ultimately responsible for his demise from multi-organ failure.
Late Outcome & Delayed Renal Function
Follow-up, Device Failure & Late mortality Excluding late mortality, twelve-month follow-up was complete in all but one OR patient (dropout rate <0.5%). He withdrew for personal reasons at 10 weeks during a period of prolonged rehabilitation following open aortic surgery. Secondary re-intervention for device failure had been required in only one EVR patient at 1-year follow-up. In this case of initially uncomplicated Zenith deployment, the pre-discharge CT scan revealed evidence of a distal attachment site endoleak that was managed successfully by endovascular limb extension. Unfortunately, the same patient required repair of the access artery pseudo-aneurysm one month later but has had no further problems since.
Only one of the five late deaths was due directly to the presenting primary surgical pathology, whose late follow-up is detailed below. Another EVR patient died at 6-months from pancreatic cancer which was not apparent on initial radiological studies. There were two late deaths due to myocardial infarction occurring at three (CR) and nine-months (OR) postoperatively. Finally, one other CR patient expired at 6-months because of a cerebro-vascular accident.
Biochemical Renal Function
Change in renal function at specific time intervals (3, 6 and 12-months) for each of the groups is shown in the box-and-whisker plots of both Figs. 1 (CrC) and 2 (CC). The annual median (IQR) change in CrC from baseline was À2.1 (5.7) mlmin À1 following EVR compared to À3.1 (8.4) mlmin À1 for OR and À4.6 (12.1) mlmin À1 for CR. Similarly, at this follow-up time there appeared to be no significant incremental difference in CC between groups with a median CC change from baseline of þ0.33 (0.22) mgl À1 after EVR and þ0.28 (0.54) mgl À1 , þ0.25 (0.74) mgl À1 for OR and CR respectively.
There was only one significant renal complication in the study that concerned Patient 11 of the study limb who developed significant dialysis-dependant renal compromise after device deployment inadvertently occluded the left renal artery during EVR. At 6-month review this was reflected biochemically by a fall in CrC to 13.4 mlmin À1 (65 mlmin À1 pre-op) and a concomitant rise in CC to 5.96 mgl À1 (1.62 mgl À1 pre-op). Interestingly, although the early DTPA scan confirmed hypoperfusion, both kidneys did in fact enhance. A renal duplex study (Day 8 post-EVR) confirmed this bilateral kidney perfusion, albeit significantly reduced on the left side (absent spectra). Also unexpected was the presence of cortical enhancement of both kidneys on a satisfactory routine post-EVR CT scan. Despite discharge home this patient required multiple readmissions with problematic fluid status and cardiac arrhythmias secondary to electrolyte imbalance, before dying at 8-months post-EVR with end-stage renal failure. No other patient in EVR, OR or CR required renal replacement therapy for any indication during the entire study period.
Radiological Renal Analysis
The one-year follow-up CT images for both the EVR and relevant OR cases were each compared to their pre-operative scans. Follow-up imaging was not performed in the 3 EVR patients who died within 1-year and considered incomplete (entire organ not visualized) in four patients. Forty EVR and 20 OR kidneys were therefore available for analysis.
There were two new isolated renal infarcts identified in the EVR group (8.3%) as opposed to none in those who underwent open AAA repair. Neither case was however accompanied with clinical or biochemical evidence of renal dysfunction. At annual follow-up bipolar renal size had not changed significantly from pre-operative values in either group (paired t-test). 
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Discussion
Since the seminal paper of Malina et al., 5 several groups have attempted to resolve the concerns of potential renal effect following EVR with uncovered bare metal supra-renal fixation. 2,6e9,15 Unfortunately, these early reports involved study groups of trans-renal EVR patients without control subjects for comparison and further evaluation of any fixation-specific renal outcome was clearly required. In 2002, Krämer et al. published the first report of fixation-specific renal outcome following EVR. In the study, which was not concerned with biochemical renal function, the post-operative CT images of 99 EVR patients (both IR and SR) were reviewed at a minimal follow-up of 12 months. Supra-renal fixation was found not to be associated with an increased incidence of renal infarcts post-EVR compared to endografts secured entirely with infra-renal fixation. 16 Soon after, the Montefiore group reported comparative renal outcome in 130 EVR (69 SR) patients with a mean follow-up of 17 months. 17 There was a significant increase in sCr from pre-operative values in both groups, yet no incremental difference between fixation-type was observed. Similarly, CrC (Cockroft-Gault) was significantly reduced for both SR and IRfixed EVR, but the extent of this fall was no different between study limbs. Post-operative renal dysfunction (defined as sCr increase > 0.5 mg/dl above baseline) developed in 10.7% (14/130) with again no difference observed between groups.
Lau et al. also described an increase in sCr following both IR and SR-EVR in their series of 89 patients. 18 Although this was quoted to be statistically significant at 1-year in the IR (and not the SR) group, the elevated median sCr remained within the normal reference range and group specific CrC values were unaffected. The clinical implications of these findings are unclear.
These reports and a review of the literature indicate a common reliance on the use of insensitive sCr methods in order to assess biochemical renal function. There are several inherent limitations with this approach. Firstly, sCr is formed by the non-enzymatic conversion of muscle creatine and phosphocreatine and hence its production rate is unstable, under direct influence from many non-renal factors (e.g. dietary preference, sex, muscle mass and surgical intervention). The Cockroft-Gault formula attempts to correct for these variables in the expression for creatinine clearance. 13 Regardless, the glomerular filtration rate (GFR) may still have to fall by at least 50% before reflected in an elevated sCr (and reduced CrC). 19e22 Finally, laboratory quantification of sCr is usually based on the Jaffé reaction, a colorimetric assay with complex-formation between creatinine and alkaline picrate ('Janovsky complex'). Unfortunately, other chromogens are present in plasma leading to falsely high levels of sCr e.g. uric acid, ketones, glucose and plasma proteins. 23 Serum cystatin C is generally accepted as a better marker of excretory renal function. 11,23e25 The low molecular weight protein is produced by all nucleated cells, is unaffected by sex or muscle mass and is freely filtered and metabolised in the kidney. It has been extensively validated by correlation with the gold-standard measurements of GFR (i.e. inulin clearance, iohexol and 51 Cr-EDTA) and typically reported superior to sCr in this respect. 24,26e30 Furthermore, CC appears more sensitive in signifying earlier reductions in GFR (25e30%) 10, 11 and therefore renal injury at a level that may be currently undetected in those EVR patients with supra-renal stent systems.
This study is not the first to employ CC as a sensitive renal index post-EVR. Aho et al. compared the short-term renal outcome of 15 EVR patients to OR controls using CC, sCr and CrC as markers of renal excretory function. This study found evidence of increased glomerular filtration in both groups in the early post-operative phase. Conversely, EVR did not protect from proximal tubular damage in either group (increased urinary N-acetyl-beta-D-glucosaminidase (NAG) to creatinine ratio) despite no patient developing clinical evidence of renal impairment. 31 Our study assessed only the excretory (glomerular) component of organ function since this is reported to offer the best clinical estimate of functional renal mass, correlating well with the severity of any observed renal dysfunction. 19, 32, 33 Over a longer 12-month followup period using cystatin C, we have found no evidence suggestive of significant renal impairment in those patients undergoing SR-EVR, conventional open AAA repair or laparotomy for colorectal resection.Admittedly, in view of the relatively small number of patients included in the study, its power is must be taken in context. Furthermore, the unavoidable use of two specific differing endograft designs within the study group may act as a source of bias. Nevertheless, the findings should promote further confidence in those advocating SR-EVR in the management of AAA.
Although there was no formalized renal protection policy within our unit, all patients with renal impairment (abnormally elevated sCr without a requirement for RRT) underwent careful intravenous fluid optimization with routine urinary catheterisation and central venous monitoring where appropriate. If possible, the administration of any contrast agent prior to EVR (within 2 weeks) was avoided and the procedural volume used during EVR was restricted to the absolute minimum required. Although it was not the policy of the unit to routinely prescribe putative 'renoprotective' agents such as dopexamine or mannitol, a peri-operative intravenous infusion was commenced if clinically indicated.
A specific intra-operative measure taken to minimize renal injury was the angiographic imaging of the renal arteries following partial stent deployment (Fig. 3a) . This was an attempt to confirm correct device positioning (Fig. 3b ) prior to complete release in order to reduce the risk of renal artery compromise by the covered segment of the stent. Unfortunately, the practice was not entirely failsafe and we describe in detail the single case of the series with inadvertent deployment error (Patient 11). This case was particularly interesting since the exact cause of renal failure was essentially unknown. Initially, the encroachment of the device on the left renal artery ostium at deployment was blamed for the acute renal failure (Fig. 3c ). Simple organ ischaemia alone cannot fully explain the clinical deterioration since DTPA, renal duplex and CT scanning revealed evidence of a maintained (albeit impaired) bilateral renal perfusion. Perhaps this reflected an initial patent renal collateral circulation that was insufficient to maintain adequate renal function. Cholesterol embolization could have also played a role but this remained unproven as no renal biopsy was performed and a post-mortem refused.
The incidence of renal infarcts in the study post-EVR was comparable to the 8.3% reported by Kramer et al. 16 One case could plausibly be explained by the intentional deployment of covered EVR stent over a small accessory renal artery that was identified on pre-operative imaging. The second instance most likely occurred due to the embolism of debris present in the region of the AAA neck during endograft manipulation and deployment. In several other cases there were transient procedural territorial renal infarcts but all had completely resolved by 12-month follow-up. Fortunately, both persistent cases were clinically insignificant and not associated with any biochemical renal derangement. Cayne et al. reported a similar functional indifference to renal infarction (using sCr and CrC methods) present in 5.8% of their 130 EVR cases. 17 Renal failure following endovascular AAA repair is generally considered multi-factorial in origin, occurring in 6% of patients with normal pre-operative kidney function. 34 The longer-term CC data yielded by this prospective work supports the hypothesis that EVR devices with uncovered bare metal suprarenal fixation have no detrimental effect per se on renal function at up to 1-year post AAA repair. Indeed, contrary to the suspected negative impact of trans-renal EVR these stents may actually in fact be protecting patients from late renal failure courtesy of improved a b c device durability and hence a reduced requirement of remedial secondary interventional procedures, each with its own potential contrast-induced nephrotoxic insult.
